The article appeared in Journal of Molecular Diagnostics, the journal of the Association for Molecular Pathology, and Lennerz et al. can be viewed as one of a quartet of articles on genomics reimbursement in this journal in 2016, 2017, and 2018.
|click to enlarge|
|Lennerz Fig. 3|
Lennerz et al. (2016) Health Care Infrastructure for Financially Sustainable Clinical Genomics. J Mol Diagn 18:697-706. [open] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397703/
Sabatini et al. (2016) Genomic Sequencing Procedure Microcosting Analysis and Health Economic Cost-Impact Analysis: Report of the AMP. J Mol Diagn 18:319-328. [open] https://www.ncbi.nlm.nih.gov/pubmed/?term=27080370
Sireci et al. (2017) Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center: Identification of Targetable Variants and Experience with Reimbursement. J Mol Diagn 19:277-287. [open] https://www.ncbi.nlm.nih.gov/pubmed/?term=28024947
Hsiao et al. (2018) The History and Impact of Molecular Coding Changes on Coverage and Reimbursement of Molecular Diagnostic Tests: Transition from Stacking Codes to the Current Molecular Code Set Including Genomic Sequencing Procedures. J Mol Diagn 20:177-183. [subscription] https://www.ncbi.nlm.nih.gov/pubmed/?term=29269278 With op-ed by Farkas, here.
For an additional current perspective, see Phillips et al. (2018) Genetic Test Availability and Spending: Where Are We Now? Where Are We Going? Health Affairs 37:710-716. [open access] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987210/ Another open access source is Concert Genetics' annual white papers on the genomics market, here.